ImmuCell Corporation Announces Results of 2026 Annual Meeting of Stockholders

ImmuCell Corporation (Nasdaq: ICCC) held its 2026 Annual Meeting of Stockholders on June 11, 2026. During the meeting, stockholders voted on several key corporate governance matters. Seven directors—Gloria J. Basse, P. Olivier te Boekhorst, Anthony A. Dimarco, Gilles Guillemette, David S. Tomsche, Kathy V. Turner, and Paul R. Wainman—were elected to one-year terms. Stockholders also approved a non-binding advisory resolution on executive compensation with 92.4% support and the company's 2025 Stock Option and Incentive Plan with 90.39% support. Additionally, an amendment to the Certificate of Incorporation was approved to reflect Delaware law provisions regarding the exculpation of officers, receiving 53.62% of the total outstanding eligible votes. Finally, the selection of Wipfli LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 99.28% of the votes cast. A total of 7,397,695 shares, or over 81% of outstanding votes, were represented at the meeting.